AIM ImmunoTech Inc. (AIM)
- GlobeNewswire
AIM ImmunoTech Reports Positive Pilot Study Data from Expanded Access Program Evaluating Ampligen® for the Treatment of Long COVID
Growing body of data supports Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”) for a Phase 2 study of Ampligen for the treatment of Post-COVID conditions Daniel Peterson, MD, the Sierra Internal Medicine in Incline Village, Nev. Daniel Peterson, MD, the Sierra Internal Medicine in Incline Village, Nev. Charles Lapp, MD, the Hunter-Hopkins Center in Charlotte, N.C. Charles Lapp, MD, the Hunter-Hopkins Center in Charlotte, N.C. OCALA, Fla., July 28, 2
- GlobeNewswire
UPDATE -- AIM Stockholder Full Value Committee Announces Director Nominations for AIM Annual Meeting and Confirms Intent to Proceed with Proxy Solicitation
AIM’s Baseless and False Allegations Demonstrate the Desperate Attempt by CEO/Director Tom Equels and Directors William Mitchell and Stewart Appelrouth to Continue to Entrench and Enrich Themselves and Waste Corporate Assets at the Expense of AIM StockholdersNEW YORK, July 21, 2022 (GLOBE NEWSWIRE) -- Jonathan Jorgl, an AIM ImmunoTech Inc. (NYSE American: AIM), (“AIM”) stockholder, together with his nominees, Robert L. Chioini and Michael Rice (collectively, the “AIM Stockholder Full Value Commi
- GlobeNewswire
AIM ImmunoTech reports additional patient data from Single-Center Named Patient Program evaluating Ampligen as maintenance therapy for advanced pancreatic cancer indicating additional progression-free and overall survival over previously published data
Professor C.H.J. van Eijck, MD, PhD Professor C.H.J. van Eijck, MD, PhD Ampligen® (rintatolimod) has demonstrated promising activity as a potential maintenance therapy after systemic chemotherapy in patients with metastatic and locally advanced pancreatic cancer (LAPC) New patient data provide further validation for advancing the development of Ampligen for the treatment of late-stage pancreatic cancer New data were recently presented by Professor C.H.J. van Eijck, MD, PhD of Erasmus Medical Cen
